^
Association details:
| Biomarker: | ABL1 T315I |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Resistance To Dasatinib In Philadelphia-Positive Leukemia Patients And The Presence Or The Selection Of Mutations At Residues 315 And 317 In The BCR-ABL Kinase Domain
Excerpt:
Eight patients had primary resistance to dasatinib (patients #1–8 in Table 1 and Figure 1). In all these patients, a T315I or a F317L mutation was already detectable before the onset of treatment or became detectable after 1 month. Interestingly, in two of these cases relapse was associated with the selection of novel amino acid substitutions – a threonine to alanine change at codon 315 (T315A) and a phenylalanine to isoleucine change at codon 317 (F317I).
DOI:
10.3324/haematol.10822
